Pharmacia and Upjohn clinical trials
Acquired by Pfizer, Apr 16, 2003 · source ↗
The registry lists 11 studies whose lead sponsor is Pharmacia and Upjohn. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 24, 2005.
Before and after it joined Pfizer
- First submitted before Pharmacia and Upjohn became part of Pfizer
- 11
- First submitted after Pharmacia and Upjohn became part of Pfizer
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Pharmacia and Upjohn11 studies
Something wrong with this grouping? Tell us on the Pfizer page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Pfizer studies →
- Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201ECompletedNCT00002094Not applicable
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected PatientsCompletedNCT00002401Not applicable
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive PatientsCompletedNCT00002322Phase 2
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3CompletedNCT00002124Phase 3
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and BabiesCompletedNCT00002210Phase 2
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take ZidovudineCompletedNCT00002312Not applicable
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3CompletedNCT00002123Phase 3
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive PatientsCompletedNCT00002236Not applicable
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- A Study of Two Anti-HIV Drug Combinations in HIV-Infected PatientsCompletedNCT00002400Not applicable
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected PatientsCompletedNCT00002211Not applicable
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer
- Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected IndividualsCompletedNCT00002087Phase 1
Sponsor listed in the registry: Pharmacia and Upjohn · First submitted before Pharmacia and Upjohn became part of Pfizer